2,374 material Form 8-K filings that 2,009 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ribbon Acquisition Corp. received a Nasdaq notice on October 30, 2026, saying its market value of listed securities has been below the $35 million minimum for 30 consecutive business days. The company has until April 28, 2027 to regain compliance, and its RIBB shares continue to trade on the Nasdaq Capital Market for now, but failing to regain compliance could lead to delisting.
Nasdaq notice dated October 30, 2026; MVLS below $35,000,000 from September 18, 2026 through October 29, 2026
Compliance deadline is April 28, 2027; MVLS must close at $35,000,000 or more for at least 10 consecutive business days
Company does not meet Nasdaq's alternative stockholders' equity or net income requirements
Shares continue to trade under RIBB; the company says it will monitor MVLS and evaluate options
Spire Missouri filed a general rate case with the Missouri Public Service Commission on November 2, 2026, requesting a total revenue requirement increase of $228 million. The filing is based on an average fiscal 2028 future test year rate base of $5.1 billion, and the commission has 11 months to review it, with new rates expected by October 2027. For shareholders, the outcome will determine how much of the utility's infrastructure investment is recovered through customer rates.
Total requested revenue increase of $228 million, including $57 million through the Infrastructure System Replacement Surcharge and $171 million in net new revenues
Proposed rates are based on an average fiscal 2028 future test year rate base of $5.1 billion, assuming a 55.0% common equity ratio and 10.5% return on equity
Company estimates the average residential bill would rise about $10 per month (11%) in western Missouri and about $13 per month (15%) in eastern Missouri if approved as filed
Missouri Public Service Commission has 11 months to consider the filing; new rates expected to be effective by October 2027
Our Bond, Inc. (OBAI) said on November 2, 2026, that Nasdaq notified it that it had regained compliance with the minimum bid price requirement. The company had received a deficiency notice on July 14, 2026, and compliance was restored because its closing bid price stayed above $1.00 for ten consecutive business days. The filing shows the listing issue is resolved but does not disclose financial results or other business developments.
Nasdaq notified the company of a bid price deficiency on July 14, 2026, under Listing Rule 5450(a)(1).
On November 2, 2026, Nasdaq confirmed the company regained compliance.
Compliance was based on a closing bid price above $1.00 for ten consecutive business days.
Nasdaq's Staff issued a Staff Delisting Determination after House of Doge's stock closed at $0.10 or less for ten consecutive trading days, and trading in the common stock will be suspended at the open on November 3, 2026. The company is evaluating whether to request a hearing before a Nasdaq Hearings Panel, and a timely request will not stay the suspension. For shareholders, the suspension could reduce liquidity and the stock price and may limit the company's ability to raise equity capital.
Trading suspension begins at the opening of business on November 3, 2026, with a Form 25-NSE to be filed with the SEC to remove the securities from Nasdaq.
A hearing request and a non-refundable $20,000 fee must reach Nasdaq by 4:00 p.m. Eastern Time on November 3, 2026.
The Staff Delisting Determination is dated October 27, 2026, based on a closing bid price of $0.10 or less from October 13 through October 26, 2026.
The company had been given until March 8, 2027 to regain the $1.00 minimum bid price and has not regained compliance; it expects to file a proxy for a reverse stock split proposal.
NRx Pharmaceuticals said the FDA approved its Abbreviated New Drug Application for Preservative-Free Ketamine ahead of the November 10, 2026 GDUFA goal date. The company says it now has commercial supply on hand to label the product and sell it to American hospitals and clinics, but the filing gives no sales, revenue or earnings figures.
FDA approved the company's ANDA for Preservative-Free Ketamine, announced October 30, 2026, ahead of the November 10, 2026 goal date.
The company says the product contains no benzethonium chloride, a preservative it describes as not GRAS-designated by the FDA.
Manufacturing is with Nephron Pharmaceuticals in West Columbia, South Carolina.
The company says it can now label the product and supply American hospitals and clinics.
Allarity Therapeutics entered a Settlement and Release Agreement with Novartis Pharma AG on October 28, 2026, resolving a liability of $4.9 million plus interest tied to a license agreement that was terminated effective January 26, 2024. Novartis agreed to accept $1.0 million as full payment, and both parties will release claims once the payment is received. Separately, the company announced on October 30, 2026 its first revenue-generating contract under its CLIA-certified laboratory services strategy, but the filing does not disclose the contract's value.
Liability owed to Novartis: $4.9 million plus interest, arising under a license agreement between Novartis and Allarity Therapeutics Europe ApS, an affiliate
Settlement payment: $1.0 million, accepted by Novartis as full payment of the liability upon receipt
Mutual releases of claims take effect upon receipt of the payment, subject to claims relating to enforcement of the agreement
October 30, 2026 press release: first revenue-generating contract under the CLIA-certified laboratory services strategy; contract value not disclosed
uniQure N.V. said the FDA accepted its Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, and granted Priority Review with a PDUFA target action date of May 1, 2027. The FDA also said it is tentatively planning an Advisory Committee meeting, with dates to be set later, and the company and FDA have aligned on the design of a confirmatory trial.
FDA accepted the BLA under the Accelerated Approval pathway and granted Priority Review
PDUFA target action date is May 1, 2027
FDA tentatively plans to discuss the application at an Advisory Committee meeting; the company will be notified once the date is set
Confirmatory trial design: randomized, standard-of-care, about 200 patients in a 2:1 ratio, Total Functional Capacity at 36 months as primary endpoint; U.S. patient screening planned to start by end of 2026
INOVIO announced on October 30, 2026 that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). The company expects to make the product available to order and ship in about 60 days and to deploy its full field team in the first quarter of 2027, and it must submit a draft confirmatory study protocol by the end of 2026. The filing does not disclose revenue, pricing, or financial projections, so the near-term financial effect on shareholders is not quantified.
FDA granted accelerated approval on October 30, 2026 for VOCERYQ in combination with the CELLECTRA 5PSP delivery device
In the efficacy population of 26 patients, 7 (27%) had a complete response after 12 months of follow-up, based on the RRP-001 study
Order-and-ship availability expected in about 60 days; full field deployment expected in Q1 2027 with Syneos Health support
Continued approval may depend on a confirmatory study; draft protocol due by end of 2026 and final protocol expected by mid-2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.